The P&MA landscape is rapidly increasing in complexity as payers respond to rising healthcare spend. While much recent discussion has focused on policy shifts such as MFN pricing, broader structural changes are reshaping global P&MA. Four trends define this shift: intensified cost containment paired with stricter value-based pricing; stronger linkage between reimbursement and local investment; structural reform of HTA and access pathways; and the rise of alternative payment and access models.
Trend 1: Global focus on cost containment and stricter value scrutiny
Cost containment is intensifying across all major markets. Governments are tightening pricing levers, increasing rebates and clawbacks, and reinforcing financial risk transfer to manufacturers. In Italy, for example, rising hospital drug overspend has led to increasing clawback obligations. In Germany, the Health Finance Commission is recommending that the rebate level be raised from 7% to 14% in 2027.
At the same time, payers are expanding formal cost-effectiveness requirements, raising the bar for pricing justification. Regions that historically relied on benchmarking or external reference pricing are moving toward structured pharmacoeconomic evaluation. In the Middle East, for example, Saudi Arabia has introduced mandatory pharmacoeconomic submissions and requires alignment with established HTA bodies such as NICE, ICER, CDA, HAS, and PBAC for innovative product registration.
In Spain, the expected Royal decree of HTA proposes that cost-effectiveness analysis be an input into drug evaluations in the future, alongside currently conducted budget impact analysis. In Japan, cost-effectiveness-based repricing is already established, with recent and ongoing refinements expanding its scope, increasing the magnitude of price adjustments, and strengthening the role of economic evaluation in pricing decisions.
Global price benchmarking and repricing mechanisms are also gaining momentum. Price benchmarking policies such as most favored nation (MFN) concepts reflect a broader political shift toward tighter international price benchmarking.
At the same time, payers are tightening scrutiny. This creates selective pockets of flexibility only where value can be clearly demonstrated. The message is clear: pricing must increasingly withstand structured, repeatable value scrutiny across the lifecycle.
Trend 2: Linking reimbursement to local investment
Governments are increasingly aligning market access incentives with local data generation and investment. This shift is reinforced by global pricing dynamics, as governments increasingly link pricing and access decisions to local economic contributions.
Germany, for example, has introduced pricing guardrail exemptions linked to local clinical trial participation; products with more than 5% local enrolment in German trial sites may benefit from greater pricing flexibility. Across the Middle East and North Africa, pricing preferences and tax incentives are being used to stimulate local manufacturing and strengthen supply resilience.
In the United Kingdom, public statements from NICE leadership suggest a growing emphasis on balancing health maximization per pound spent with inward investment considerations. This signals a broader shift: access is no longer driven solely by clinical and economic value but also by local relevance and economic footprint.
For manufacturers, global launch strategy must integrate pricing, access, clinical trial design, and footprint decisions from the outset.
Trend 3: Structural P&R reforms and new access pathways
Across major markets, pricing and reimbursement systems are being structurally reshaped. While pricing authority remains national, regions are moving toward greater alignment in how clinical value is assessed. This shift is aimed at improving efficiency, strengthening scrutiny, and reducing disparities in access.
In Europe, the EU HTA Regulation introduces Joint Clinical Assessments (JCA), establishing a common clinical evidence review across Member States. The reform goes beyond procedural coordination: it standardizes how clinical benefit is evaluated, even though pricing decisions remain national. Broader intra-regional collaboration reinforces this direction. The Joint Nordic HTA Bodies now cover all Nordic countries, including Iceland. The Czech Republic is exploring closer cooperation with BeNeLuxA for joint assessments and potential negotiations. Together, these initiatives further consolidate technical evaluation standards within the region.
In Asia-Pacific, harmonization is more methodological than institutional but increasingly visible. Through networks such as HTAsiaLink, HTA bodies across Thailand, Taiwan, Malaysia, Singapore, South Korea, Japan, and others are aligning on evidence expectations, particularly around real-world evidence. While joint assessments are limited, appraisal frameworks and data requirements are gradually converging.
Across Latin America, regional platforms such as RedETSA are strengthening cooperation in HTA methodologies and evidence standards. National decision-making remains sovereign, but technical assessment approaches are becoming more consistent across countries.
At the same time, payers are introducing new access pathways to manage uncertainty for high-cost therapies. China’s “Category C” pathway enables conditional coverage for innovative medicines outside the National Reimbursement Drug List (NRDL) through commercial insurance. In Australia, recent HTA reforms have expanded the use of managed entry agreements and introduced bridging funding mechanisms, creating more flexible access pathways to accelerate patient access while managing financial risk.
The direction is clear: clinical evidence standards are tightening and increasingly aligned within regions, even as pricing remains country-specific. For manufacturers, this raises the bar for early comparator planning and real-world evidence generation while creating structured opportunities for conditional and staged access.
Trend 4: Alternative payment models on the rise
Alternative payment models are gaining relevance, particularly where traditional reimbursement pathways are restrictive. Payers remain cautious about funding therapies with high upfront costs and uncertain long-term value, especially in areas such as preventive or early-stage interventions.
At the same time, global pricing dynamics are increasing pressure on manufacturers. As scrutiny grows around international price differentials, there is limited flexibility to increase prices in many markets, while cost-effectiveness thresholds and payer constraints remain binding.
Manufacturers are therefore exploring both alternative payment and access models. Hybrid approaches, including direct-to-consumer models, are emerging in selected markets, particularly where reimbursement gaps exist. In parallel, companies are increasingly targeting alternative access routes, such as private markets or out-of-pocket segments, to preserve pricing flexibility and expand access.
While these models can accelerate uptake and diversify revenue streams, they introduce operational complexity, equity concerns, and risks related to price anchoring and future payer negotiations.
What pharma leaders must do now
Value standards are becoming more harmonized across regions, evidence expectations are rising, and access pathways are being redesigned to balance faster patient access with fiscal discipline. At the same time, pricing decisions are increasingly interconnected across markets through reference pricing, joint assessments, and price benchmarking mechanisms.
These trends cannot be viewed in isolation. They reinforce each other and are expected to intensify, creating structural tensions between global pricing pressure and increasingly stringent local access requirements.
For pharmaceutical companies, this environment requires more than incremental adaptation. Pharma leaders must therefore rethink evidence generation - particularly strengthening cost-effectiveness and value argumentation - leverage opportunities from growing payer collaboration to redefine the launch sequencing and explore novel value levers.
At Simon-Kucher, our healthcare & life sciences experts help organizations navigate this complexity, optimizing pricing, market access, evidence, and commercial strategy to unlock sustainable growth. To learn more about how we can support your organization, contact us today.
